title: Radiation-induced esophagitis exacerbated by everolimus.
abstract: BACKGROUND
  Everolimus, a potent mammalian target of rapamycin (mTOR) inhibitor, has shown anticancer activity against various types of cancer, including renal cell carcinoma (RCC); however, little information is available on the efficacy and safety of the combination of everolimus and radiotherapy. We report a case of radiation-induced esophagitis that might have been exacerbated by the sequential administration of everolimus.
  
  
  METHODS
  A 63-year-old Japanese man with RCC complained of back pain, and magnetic resonance imaging revealed vertebral metastases. He received radiotherapy (30 Gy/10 fractions) to the T6-10 vertebrae. Everolimus was administered immediately after the completion of radiotherapy. One week later, he complained of dysphagia, nausea and vomiting. An endoscopic examination of the esophagus showed erosive esophagitis in the middle to lower portions of his thoracic esophagus, corresponding to the irradiation field.
  
  
  CONCLUSIONS
  Clinicians should be aware that everolimus might lead to the unexpected exacerbation of radiation toxicities.
authors.affiliation: Departments of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Miura
authors.forename: Koichi
authors.initials: K
authors.lastname: Suyama
authors.forename: Akihiko
authors.initials: A
authors.lastname: Shimomura
authors.forename: Jimpei
authors.initials: J
authors.lastname: Miyakawa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Uki
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Okaneya
authors.forename: Toshimi
authors.initials: T
authors.lastname: Takano
keywords: Mammalian target of rapamycin; Radiation recall syndrome; Renal cell carcinoma
references.citation: Clin Cancer Res. 2009 Jan 15;15(2):589-96
references.pmid: 19147764
references.citation: Onkologie. 2007 Apr;30(4):209-14
references.pmid: 17396045
references.citation: N Engl J Med. 1996 Sep 19;335(12):865-75
references.pmid: 8778606
references.citation: Oncogene. 2005 Aug 18;24(35):5414-22
references.pmid: 15940265
references.citation: Clin Cancer Res. 2010 Nov 15;16(22):5573-80
references.pmid: 20921209
references.citation: Cancer Res. 2002 Dec 15;62(24):7291-7
references.pmid: 12499272
references.citation: Ann Oncol. 2011 Feb;22(2):485-6
references.pmid: 21278224
references.citation: Cancer Treat Rev. 2005 Nov;31(7):555-70
references.pmid: 16168567
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):468-75
references.pmid: 20864273
references.citation: Radiat Res. 2011 Feb;175(2):214-24
references.pmid: 21268715